Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUK<i>one</i> randomized dose selection trial
Steve Schey(King's College London), James Cavet(The Christie NHS Foundation Trust), Faith E. Davies(NYU Langone Health), Avie‐Lee Tillotson(University of Leeds), Gordon Cook(University of Leeds), Guillermo Ortí(Hospital Universitari i Politècnic La Fe), Mark Cook(Université Paris Cité), Curly Morris(Belfast Health and Social Care Trust), Debbie Sherratt(University of Leeds), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Sarah Brown(University of Leeds), Gareth J. Morgan(Hywel Dda University Health Board), Cathy Williams(The University of Texas System), Walter M. Gregory(University of Leeds), Jamie Cavenagh(St Bartholomew's Hospital), Louise Flanagan(University of Leeds)
Cited by 20
Related Papers
The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report
|The Lancet|2019|3.1k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k